BA
VRTX icon

Bridgewater Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridgewater Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$503K Buy
1,109
+33
+3% +$15.4K 0.03% 246
2025
Q4 		$496K Buy
1,076
+7
+0.7% +$3.02K 0.03% 259
2025
Q3 		$445K Sell
1,069
-28
-3% -$11.7K 0.03% 272
2025
Q2 		$514K Sell
1,097
-16
-1% -$7.37K 0.04% 241
2025
Q1 		$561K Buy
+1,113
New +$519K 0.05% 204

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bridgewater Advisors's VRTX Position: Q1 2026 in Review

Bridgewater Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q1 2026, buying an estimated $15.4K and bringing the position to 1,109 shares worth $503K. The position accounts for 0.03% of the portfolio, ranked #246.

Bridgewater Advisors first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $561K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bridgewater Advisors held 1,109 shares of Vertex Pharmaceuticals worth $503K as of Q1 2026.
  • Bridgewater Advisors bought 33 Vertex Pharmaceuticals shares in Q1 2026, an estimated $15.4K.
  • Vertex Pharmaceuticals made up 0.03% of Bridgewater Advisors's portfolio in Q1 2026, its #246 holding.
  • Bridgewater Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Bridgewater Advisors's Vertex Pharmaceuticals position peaked at $561K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bridgewater Advisors's 13F filing for Q1 2026, filed 14 May 2026.